Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IMNM

Immunome Inc

Oct 27 • 03:28PM ET

16.79

+1.10 7.01 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA NVAX SRPT NTLA CRSP PFE GILD BNTX BEAM

| Held by: VTI IWM XBI IWO VXF SCHA VTWO IDNA IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-3.09	Insider Own	8.37%	Shs Outstand	87.01M	Perf Week	3.32%
Market Cap	1.46B	Forward P/E	-	EPS next Y	-2.37	Insider Trans	0.07%	Shs Float	79.76M	Perf Month	44.87%
Enterprise Value	1.20B	PEG	-	EPS next Q	-0.57	Inst Own	85.32%	Short Float	19.10%	Perf Quarter	58.40%
Income	-212.39M	P/S	116.08	EPS this Y	57.86%	Inst Trans	8.73%	Short Ratio	12.45	Perf Half Y	95.69%
Sales	12.59M	P/B	5.43	EPS next Y	-12.56%	ROA	-71.69%	Short Interest	15.24M	Perf YTD	58.10%
Book/sh	3.09	P/C	5.45	EPS next 5Y	25.10%	ROE	-81.20%	52W High	17.32 -3.04%	Perf Year	44.74%
Cash/sh	3.08	P/FCF	-	EPS past 3/5Y	-32.63% -38.15%	ROIC	-77.68%	52W Low	5.15 226.01%	Perf 3Y	285.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	79.25%	Volatility	6.44% 8.34%	Perf 5Y	29.25%
Dividend TTM	-	EV/Sales	95.12	EPS Y/Y TTM	59.89%	Oper. Margin	-1513.45%	ATR (14)	1.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.13	Sales Y/Y TTM	16.74%	Profit Margin	-1687.08%	RSI (14)	67.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.13	EPS Q/Q	17.24%	SMA20	15.14%	Beta	1.95	Target Price	24.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	69.84%	SMA50	42.55%	Rel Volume	0.67	Prev Close	15.69
Employees	118	LT Debt/Eq	0.02	Earnings	Aug 06 AMC	SMA200	72.55%	Avg Volume	1.22M	Price	16.79
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.23% 381.82%	Trades		Volume	754,650	Change	7.01%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-25	Initiated	Goldman	Buy	$26
Sep-05-25	Initiated	Craig Hallum	Buy	$26
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
08:00AM	Loading…
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
10:29AM	Loading…
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
04:05PM	Loading…
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)
May-20-24 11:14AM	Immunome Completes Purchase of Antibodies From Atreca (MT Newswires)
08:00AM	Immunome Announces Completion of Purchase of Assets from Atreca (Business Wire)
May-17-24 08:51AM	Immunome Appoints Max Rosett as CFO (MT Newswires)
08:00AM	Immunome Announces Promotion of Max Rosett to Chief Financial Officer (Business Wire)
May-14-24 01:54PM	IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.70%
09:10AM	Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:00AM	Immunome to Present at 2024 Bank of America Healthcare Conference (Business Wire)
May-02-24 08:00AM	Immunome Appoints Kinney Horn as Chief Business Officer (Business Wire)
Apr-30-24 07:29AM	--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target (MT Newswires)
Apr-26-24 10:00AM	Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-25-24 08:26AM	Immunome Appoints Sandra M. Swain to Board of Directors (Business Wire)
Apr-05-24 08:00AM	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-28-24 11:53PM	IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.41%
04:02PM	Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets (Business Wire)
Mar-26-24 08:00AM	Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala (Business Wire) +5.79%
08:00AM	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome (GlobeNewswire)
Mar-18-24 05:44AM	Arrayjets ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies (Business Wire)
Mar-07-24 08:00AM	Immunome to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-01-24 08:00AM	Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference (Business Wire) +5.17%
Feb-20-24 08:15AM	Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (Business Wire) -10.99%
08:00AM	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (GlobeNewswire)
Feb-16-24 04:05PM	Immunome Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +14.74%
Feb-13-24 10:38PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire)
04:05PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-07-24 08:34AM	Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up (Zacks) +7.83%
Feb-06-24 09:20AM	Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks (FierceBiotech.com) +36.91%
08:00AM	Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (Business Wire)
Feb-05-24 08:00AM	Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.91%
Jan-04-24 08:00AM	Immunome Appoints Phil Roberts as Chief Technical Officer (Business Wire)
Jan-03-24 08:00AM	Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.27%

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Higgins Jack	Chief Scientific Officer	Sep 10 '25	Option Exercise	1.35	22,000	29,700	40,729	Sep 11 09:04 PM
BIENAIME JEAN JACQUES	Director	Jun 03 '25	Buy	9.38	5,000	46,900	36,415	Jun 03 09:21 PM
Higgins Jack	Chief Scientific Officer	Mar 27 '25	Option Exercise	1.35	5,200	7,020	18,729	Mar 28 05:54 PM
BIENAIME JEAN JACQUES	Director	Mar 25 '25	Buy	7.78	7,800	60,684	31,415	Mar 26 04:05 PM
SIEGALL CLAY B	President and CEO	Mar 26 '25	Buy	7.29	137,100	999,459	806,736	Mar 26 04:03 PM
BIENAIME JEAN JACQUES	Director	Mar 24 '25	Buy	8.21	7,000	57,470	23,615	Mar 25 05:18 PM
Tsai Philip	Chief Technology Officer	Mar 24 '25	Buy	8.42	12,300	103,566	33,300	Mar 25 05:15 PM
SIEGALL CLAY B	President and CEO	Jan 31 '25	Buy	7.75	150,000	1,162,500	669,636	Feb 03 09:01 PM
SIEGALL CLAY B	President and CEO	Nov 21 '24	Buy	9.54	66,057	630,263	485,693	Nov 25 08:41 AM
SIEGALL CLAY B	President and CEO	Nov 22 '24	Buy	9.78	33,943	331,918	519,636	Nov 25 08:41 AM
Lechleider Robert	Chief Medical Officer	Nov 21 '24	Buy	9.48	15,805	149,800	15,805	Nov 25 08:35 AM
Tsai Philip	Chief Technology Officer	Nov 21 '24	Buy	9.43	21,000	198,030	21,000	Nov 25 08:33 AM

Open in Screener

BMRN

Biomarin Pharmaceutical Inc

Oct 27 • 03:28PM ET

53.41

-1.07 -1.96 %

Healthcare • Biotechnology • USA • NASD

BMRN Biomarin Pharmaceutical Inc daily Stock Chart

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: IJH VTI VB VBK VXF XBI MDY IBB IJJ SPMD

Index	-	P/E	15.82	EPS (ttm)	3.38	Insider Own	1.49%	Shs Outstand	192.00M	Perf Week	0.64%
Market Cap	10.26B	Forward P/E	12.07	EPS next Y	4.42	Insider Trans	-0.07%	Shs Float	189.15M	Perf Month	-0.82%
Enterprise Value	9.44B	PEG	0.46	EPS next Q	0.81	Inst Own	98.56%	Short Float	4.50%	Perf Quarter	-8.28%
Income	657.24M	P/S	3.37	EPS this Y	73.58%	Inst Trans	-2.18%	Short Ratio	3.85	Perf Half Y	-15.20%
Sales	3.04B	P/B	1.70	EPS next Y	15.33%	ROA	9.05%	Short Interest	8.51M	Perf YTD	-18.74%
Book/sh	31.39	P/C	7.16	EPS next 5Y	34.14%	ROE	11.62%	52W High	73.51 -27.34%	Perf Year	-23.68%
Cash/sh	7.46	P/FCF	14.76	EPS past 3/5Y	- -	ROIC	9.92%	52W Low	51.56 3.58%	Perf 3Y	-39.79%
Dividend Est.	-	EV/EBITDA	10.39	Sales past 3/5Y	15.43% 10.98%	Gross Margin	78.76%	Volatility	2.36% 2.47%	Perf 5Y	-31.45%
Dividend TTM	-	EV/Sales	3.10	EPS Y/Y TTM	153.58%	Oper. Margin	27.12%	ATR (14)	1.42	Perf 10Y	-50.93%
Dividend Ex-Date	-	Quick Ratio	3.60	Sales Y/Y TTM	17.38%	Profit Margin	21.62%	RSI (14)	45.49	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	5.56	EPS Q/Q	124.28%	SMA20	-0.92%	Beta	0.33	Target Price	95.29
Payout	0.00%	Debt/Eq	0.10	Sales Q/Q	16.77%	SMA50	-3.23%	Rel Volume	1.47	Prev Close	54.48
Employees	3040	LT Debt/Eq	0.10	Earnings	Oct 27 AMC	SMA200	-11.24%	Avg Volume	2.21M	Price	53.41
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.89% 8.28%	Trades		Volume	3,004,196	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	H.C. Wainwright	Neutral	$60
Sep-03-25	Initiated	Raymond James	Outperform	$85
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116

Show Previous Ratings

Oct-25-25 11:03PM	BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 12:43AM	3 of Wall Street's Favorite Stocks to Target This Week (StockStory)
Oct-23-25 10:00AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 04:05PM	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET (PR Newswire)
Oct-17-25 09:54PM	Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) (Insider Monkey)
12:57AM	Loading…
Oct-08-25 12:57AM	Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? (Insider Monkey)
Oct-06-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Oct-02-25 09:46AM	Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors (Insider Monkey)
Oct-01-25 08:08PM	BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-30-25 04:01AM	Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT (Insider Monkey)
Sep-19-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Sep-18-25 12:39PM	BioMarin Pharmaceutical Inc.'s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials (Insider Monkey)
Sep-17-25 02:27PM	BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Sep-16-25 12:37PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
09:51AM	Loading…
09:51AM	New Study Results Highlight BioMarin's VOXZOGO Efficacy in Children (Insider Monkey)
Sep-15-25 11:31PM	Reflecting On Therapeutics Stocks' Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) (StockStory)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-09-25 03:11PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Sep-08-25 02:39PM	Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? (Zacks)
11:46AM	Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today (StockStory)
09:49AM	Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls (The Fly)
09:00AM	BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
04:00AM	Inside pharmas race to deliver new treatments for dwarfism (Pharma Voice)
04:00AM	Can drug developers help kids with dwarfism reach new heights? (Pharma Voice)
Sep-06-25 11:05AM	BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism (PR Newswire)
Sep-03-25 11:30AM	BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-01-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Aug-31-25 12:10AM	What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? (Insider Monkey)
Aug-28-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:00AM	Loading…
Aug-27-25 09:00AM	BioMarin to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 11:29AM	Bernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Aug-22-25 11:57PM	Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86 (Insider Monkey)
Aug-20-25 12:02AM	2 Reasons to Watch BMRN and 1 to Stay Cautious (StockStory)
Aug-19-25 12:08AM	Predicting the Next Rule Breaker Buyout (Motley Fool)
Aug-18-25 09:50AM	BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Aug-13-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Aug-12-25 11:53PM	The Top 5 Analyst Questions From BioMarin Pharmaceutical's Q2 Earnings Call (StockStory)
11:41PM	BMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results (StockStory)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
09:10AM	Leerink Partners Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $105 (Insider Monkey)
Aug-08-25 03:42AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Aug-07-25 12:44AM	1 Healthcare Stock on Our Watchlist and 2 We Find Risky (StockStory)
Aug-06-25 07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
Aug-05-25 10:17AM	BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View (Zacks)
03:02AM	BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-04-25 06:00PM	BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:20PM	BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:47PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars (StockStory)
04:20PM	BioMarin: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS (PR Newswire)
Aug-03-25 02:00PM	Palantir, Advanced Micro, Walt Disney, Pfizer, ZoomInfo, and More Stocks to Watch This Week (Barrons.com)
Aug-02-25 11:04PM	BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jul-28-25 10:00AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
02:07AM	Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT (Insider Monkey)
Jul-23-25 01:18PM	Will Escalating Medical Costs Dampen Centene's Q2 Earnings? (Zacks)
Jul-22-25 09:00AM	BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET (PR Newswire)
Jul-16-25 12:45PM	Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice (Zacks)
09:55AM	Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet (Zacks)
03:51AM	Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money (Motley Fool)
Jul-14-25 11:34PM	Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks (StockStory)
09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Jul-11-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Jul-10-25 11:26PM	Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside (Insider Monkey)
12:10PM	Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:08AM	BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma (Insider Monkey)
Jul-08-25 09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
Jul-01-25 08:45AM	BioMarin Announces Completion of Acquisition of Inozyme (PR Newswire)
Jun-28-25 04:16AM	BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A (Insider Monkey)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jun-26-25 04:19AM	The Top 5 Analyst Questions From BioMarin Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-25-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Jun-24-25 09:00AM	BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress (PR Newswire)
Jun-23-25 01:36AM	Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating (Insider Monkey)
12:01AM	2 Reasons to Watch BMRN and 1 to Stay Cautious (StockStory)
Jun-20-25 05:00PM	Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders (GlobeNewswire)
Jun-15-25 05:26AM	Jim Cramer on BioMarin: "I Don't Think It Works Now" (Insider Monkey)
Jun-11-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-09-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-05-25 03:06AM	Here Are All 6 Stocks I've Bought Through 5 Months of 2025 (Motley Fool)
May-28-25 11:40AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? (Zacks)
May-26-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
May-22-25 12:35PM	Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More (Zacks)
09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
04:22AM	BioMarin agrees to acquire Inozyme for $270m (Pharmaceutical Technology)
May-18-25 08:17AM	BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition (Insider Monkey)
May-17-25 01:30PM	Leerink bullish on BioMarin following Inozyme deal, expects additional BD (TipRanks)
May-16-25 09:37AM	How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain (Investor's Business Daily)
09:37AM	BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover (Investor's Business Daily)
08:26AM	BioMarin to buy rare disease drugmaker Inozyme for $270M (BioPharma Dive)
07:30AM	BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma (PR Newswire)
06:34AM	BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress (StockStory)
May-14-25 07:48AM	BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-12-25 09:05AM	BioMarin Presents New Data for VOXZOGO (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings (PR Newswire)
May-09-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Nov 12 '24	Sale	66.37	5,278	350,324	68,909	Nov 14 02:44 PM
Guyer Charles Greg	Officer	Nov 12 '24	Proposed Sale	66.37	5,278	350,324		Nov 12 02:27 PM

IMNM

Immunome Inc

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience